SB227 • 2026

Cap cost sharing for prescription insulin drugs

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor: Hearcel F. Craig
Last action
Official status: As Introduced
Effective date: Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Cap cost sharing for prescription insulin drugs

To enact section 3902.65 of the Revised Code to cap cost sharing for prescription insulin drugs.

What This Bill Does

To enact section 3902.65 of the Revised Code to cap cost sharing for prescription insulin drugs.

Limits and Unknowns

This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

Ohio Legislature
As Introduced

Official Summary Text

To enact section 3902.65 of the Revised Code to cap cost sharing for prescription insulin drugs.

Current Bill Text

Read the full stored bill text

As Introduced

136th
General Assembly

Regular
Session
S. B. No. 227

2025-2026

Senator Craig

Cosponsors: Senators Manning, Ingram,
Antonio, Hicks-Hudson, Weinstein

A
BILL

To
enact section
3902.65

of the Revised
Code

to cap cost sharing for prescription insulin drugs.

BE
IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

Section
1.
That
section
3902.65

of the Revised Code be enacted to read as follows:

Sec.
3902.65.
(A)
As used in this section, "prescription insulin drug" means
a prescription drug that contains insulin and is used to treat
diabetes.

(B)
Notwithstanding section 3901.71 of the Revised Code, no health plan
issuer that provides coverage for prescription insulin drugs pursuant
to the terms of a health benefit plan amended, issued, or renewed on
or after the effective date of this section shall require cost
sharing for a covered prescription insulin drug in an amount
exceeding thirty-five dollars per thirty-day supply of the drug,
regardless of the amount or type of insulin needed to fill the
covered person's prescription. The cost sharing shall be charged on a
per-prescription-fill basis.